title: Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.
abstract: Epstein-Barr virus (EBV)-negative Burkitt's lymphoma (BL) cell lines have been converted to EBV genome positivity by in vitro infection with the transforming EBV strain B95.8 and with the nontransforming mutant strain P3HR1, which has a deletion in the gene encoding the nuclear antigen EBNA2. These B95.8- and P3HR1-converted lines have been compared for their patterns of expression of EBV latent genes (i.e., those viral genes constitutively expressed in all EBV-transformed lines of normal B-cell origin) and for their recognition by EBV-specific cytotoxic T lymphocytes (CTLs), in an effort to identify which latent gene products provide target antigens for the T-cell response. B95.8-converted lines on several different EBV-negative BL-cell backgrounds all showed detectable expression of the nuclear antigens EBNA1, EBNA2, and EBNA3 and of the latent membrane protein (LMP); such converts were also clearly recognized by EBV-specific CTL preparations with restriction through selected human leukocyte antigen (HLA) class I antigens on the target cell surface. The corresponding P3HR1-converted lines (lacking an EBNA2 gene) expressed EBNA1 and EBNA3 but, surprisingly, showed no detectable LMP; furthermore, these converts were not recognized by EBV-specific CTLs. Such differences in T-cell recognition were not due to any differences in expression of the relevant HLA-restricting determinants between the two types of convert, as shown by binding of specific monoclonal antibodies and by the susceptibility of both B95.8 and P3HR1 converts to allospecific CTLs directed against these same HLA molecules. The results suggest that in the normal infectious cycle, EBNA2 may be required for subsequent expression of LMP and that both EBNA2 and LMP (but not EBNA1 or EBNA3) may provide target antigens for the EBV-specific T-cell response.
authors.affiliation: Department of Cancer Studies, University of Birmingham, United Kingdom.
authors.forename: R J
authors.initials: RJ
authors.lastname: Murray
authors.forename: L S
authors.initials: LS
authors.lastname: Young
authors.forename: A
authors.initials: A
authors.lastname: Calender
authors.forename: C D
authors.initials: CD
authors.lastname: Gregory
authors.forename: M
authors.initials: M
authors.lastname: Rowe
authors.forename: G M
authors.initials: GM
authors.lastname: Lenoir
authors.forename: A B
authors.initials: AB
authors.lastname: Rickinson
mesh_terms: D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology / Q000502:physiology; D001402:B-Lymphocytes / Q000276:immunology / Q000382:microbiology*; D002051:Burkitt Lymphoma / Q000473:pathology; D002460:Cell Line; D002472:Cell Transformation, Viral; D019309:Epstein-Barr Virus Nuclear Antigens; D005786:Gene Expression Regulation; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000472:pathogenicity / Q000502:physiology*; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000382:microbiology
chemical_list: D000956:Antigens, Viral; D019309:Epstein-Barr Virus Nuclear Antigens